Incyte Wins $50M from Lilly as RA Drug Enters Phase III
Incyte won a $50 million milestone payment from Eli Lilly tied to formal initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib, Incytes oral JAK1/JAK2 inhibitor (formerly INCB28050).
Incyte won a $50 million milestone payment from Eli Lilly tied to formal initiation of the rheumatoid arthritis (RA) Phase III program for baricitinib, Incyte’s oral JAK1/JAK2 inhibitor (formerly INCB28050).
Incyte and Lilly disclosed the payment today, two days after the companies presented 24-week results from a Phase IIb study of baricitinib in patients with moderate-to-severe RA who had an inadequate response to treatment with methotrexate.
At the annual meeting of the American College of Rheumatology in Washington, D.C., the companies released data showing that compared with patients taking placebo, patients taking baricitinib 4 mg or 8 mg once daily reported significant differences in ACR20, ACR50, and ACR70 responses—meaning at least 20%, 50%, or 70% improvement in both the tender joint count and swollen joint count, and in at least three of five other core set measures.
The best response was in patients in the 4 mg dosage; 78% of all enrolled patients reached ACR20, followed by 73% reaching ACR20 in the 8 mg dosage. The least response was seen in the 10% of patients on the 2 mg dosage who attained ACR70.
“Patients experienced improvement with baricitinib as early as week 2 that was sustained through week 24," said Mark Genovese, M.D., the James Raitt professor of medicine and co-chief, division of immunology and rheumatology at Stanford University School of Medicine, and steering committee member for the study. "The percentage of patients achieving ACR50 and ACR70 increased over time and no unexpected safety findings emerged with continued dosing."
The study also included a large sub-study of 154 patients using magnetic resonance imaging to examine the effect of different doses of baricitinib on joint changes in a subgroup of patients with erosive RA and inadequate response to treatment with methotrexate.
Through 24 weeks, patients saw statistically significant improvement in both the Total Inflammation Score and the Total Joint Damage Score for both 4 mg and 8 mg baricitinib doses compared with placebo at 12 weeks.
For Phase III, plans call for four RA studies on the safety and efficacy of baricitinib 2 mg and 4 mg once daily in patients with active RA who are methotrexate-naive, biologic-naive, or biologic-experienced. Patients completing any of the four studies will be eligible for enrollment in a fifth study, a long-term extension.
Lilly is conducting the Phase III program as part of the exclusive worldwide License, Development and Commercialization Agreement for baricitinib both companies entered into in December 2009. At the time, Incyte received a $90 million up-front payment from Lilly, with eligibility for up to $665 million tied to development, regulatory, and commercialization milestones, as well as tiered, double-digit royalty payments on future global sales with rates ranging up to 20% if a product is successfully commercialized.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance